86 results about "Treatment and control groups" patented technology

The invention relates to the technical field of analysis and detection, in particular to a method for identifying free nucleic acid and nucleic acid wrapped by a carrier based on nuclear magnetic resonance phosphorus spectrums.The method comprises the following steps that 1, the free nucleic acid serves as a contrast, nuclear magnetic resonance phosphorus spectrum detection is conducted, and a nuclear magnetic phosphorus spectrogram of the free nucleic acid is obtained; (2) taking the nucleic acid combined with the carrier as an experimental group, and performing nuclear magnetic resonance phosphorus spectrum detection under the same condition to obtain a phosphorus spectrogram of the experimental group; and (3) comparing the characteristic changes of peak positions, peak shapes, peak heights, peak areas and the like of the experimental group and the control group to identify the free nucleic acid and the nucleic acid wrapped by the carrier. The method has good accuracy, repeatability and stability, can be used for nondestructive testing, and is suitable for analyzing sensitive samples. The method can be used for detecting the binding condition of a carrier and nucleic acid in a nucleic acid drug, predicting the encapsulation efficiency and release rate of the nucleic acid drug, and providing an important analysis tool for opening, production and quality control of the nucleic acid drug.

The invention discloses a patient report outcome management method and system, and relates to the technical field of medical information. The method comprises the following steps: firstly, dividing role permissions, and defining an information viewing and operating range; key operation behaviors are collected and coded according to a unified format to generate a role behavior chain; extracting a content degradation factor from the behavior chain, determining a weight through a random forest algorithm, and carrying out weighted calculation on a content degradation index; a term vector is generated by using a biomedical model, and a medical compliance index is calculated through a cosine distance; content optimization indexes are calculated by fusing the two indexes, and fields needing to be optimized are marked by comparing threshold values; when the field content is the content optimization item, optimizing the original field content; and comparing data of the experimental group and the control group through A / B test, calculating to obtain an optimization effect index, and automatically replacing the optimization effect index with optimization content if the optimization effect index reaches the standard to form a final patient report. According to the optimization effect index, whether the optimized field content is replaced with the original field content or not is determined, and a final patient report is obtained.

The invention provides an applicable population screening method and application of a glioma dry-like cell sensitized DC vaccine, peripheral blood of a patient before and after inoculation of the glioma dry-like cell sensitized DC vaccine is obtained, mononuclear cells are extracted, CD8 + T cells are respectively separated from the mononuclear cells through a magnetic bead sorting method, and the CD8 + T cells are separated from the mononuclear cells. The method comprises the following steps: uniformly inoculating CD8 < + > T cells into an ELISPOT cell culture plate coated with an IFN-gamma antibody for culture, respectively setting an experimental group and a positive control group for culture, adding A2B5 < + > glioma cell lysis buffer into the experimental group and adding phytohemagglutinin into the positive control group, and carrying out ELISPOT staining on the cultured cells to obtain the secretion amount of FN-gamma before and after treatment of a patient. According to the secretion amount of the FN-gamma, patients with specific immune response to the glioma dry-like cell sensitization DC vaccine are screened, so that the glioma dry-like cell sensitization DC vaccine is conveniently popularized and applied, and the immune mechanism of the glioma dry-like cell sensitization DC vaccine is researched.

The invention provides application of a sperm tRNA (transfer ribonucleic acid) derived fragment 5 'tRF-Glu-CTC in prediction of development potential of assisted reproductive embryos. The expression of a tRNA derived fragment 5 'tRF-Glu-CTC in a sperm sample is detected, the abnormal expression of the sperm specific tRNA derived fragment 5' tRF-Glu-CTC in a DFI increase patient is verified, and the analysis on the correlation with clinical data and reproductive outcome of the patient prompts that the 5 'tRF-Glu-CTC molecular marker has significant correlation with the reproductive outcome, so that the 5' tRF-Glu-CTC molecular marker can be used for detecting the expression of the sperm specific tRNA derived fragment 5 'tRF-Glu-CTC in the DFI increase patient. The embryonic development potential can be effectively predicted, and a biomarker is provided for assisted reproduction treatment. In different experimental groups, the 5 'tRF-Glu-CTC can significantly improve the prediction precision, and shows good prediction performance in different clinical data. The detection method based on the fragment is expected to become a new tool for evaluating the assisted reproduction curative effect, the reproduction treatment scheme is further optimized, and the success rate is improved.

The present invention discloses a microecological animal model for obstructive sleep apnea syndrome, which includes steps such as constructing a fitting model for the changing trend of OSA events, selecting target animals and performing pretreatment, preparing an animal model, obtaining fecal samples, and DNA extraction and 16S rRNA high-throughput sequencing. By constructing a fitting model for the changing trend of respiratory sleep apnea events, the present invention obtains the fitting mathematical relationship between the number of apnea and time, and establishes an animal model with SD rats. According to the obtained fitting mathematical relationship, the animal model of the experimental group is given periodic oxygen supply to establish an intestinal flora model for studying obstructive sleep apnea syndrome, which can simulate the actual physiological environment during sleep of patients. According to the changing trend of the duration of patients' respiratory sleep apnea events, a microecological animal model more consistent with the actual situation is established, making the detection result of the flora structure more accurate.

The invention discloses an EST protease activity detection method which comprises the following steps: a, setting an EST experimental group, a negative control group and a blank control group; b, carrying out incubation reaction on the EST experimental group, the negative control group and the blank control group to obtain respective reaction mixtures; c, detecting the influence of the reaction mixture on breast cancer cell proliferation to obtain the proliferation rate of each group; and d, calculating the enzymatic activity of the EST protein. The method disclosed by the invention is simple and easy to implement, good in repeatability and capable of effectively detecting the activity of the EST protease.

The application discloses application of a CCL15 neutralizing antibody in preparation of a medicine for inhibiting growth of liver cancer, and comprises the following steps: S1, constructing a mouse liver cancer PDX model and performing passage; S2, randomly dividing the immunodeficient mouse after passage into a control group and an experimental group, and performing dosing treatment on the control group and the experimental group every three days; S3, PDX model tumor tissue evaluation, stripping tumor tissues after 11 times of dosing of the control group and the experimental group, and respectively observing and recording the volume and weight of the tumor tissues of the control group and the experimental group; the method for inhibiting growth of liver cancer provided by the application, CCL15 acts on the stellate cells to activate the stellate cells and make the expression spectrum of the stellate cells change significantly, the CCL15 neutralizing antibody has an anti-tumor effect in the liver cancer PDX model through injection, and tumor-derived CCL15 can indirectly promote growth of liver cancer cells by activating the hepatic stellate cells.

The invention relates to the field of radioactive substance toxicity detection, in particular to a method for evaluating low-activity radioactive 137Cs toxicity based on oryzias latipes, which comprises the following steps: step 1, setting culture conditions of the oryzias latipes, and starting an exposure experiment in 137Cs with adjusted exposure parameters; 2, observing reproductive state parameters of the oryzias latipes after the exposure experiment; 3, dissecting the oryzias latipe and taking gonad tissues; and 4, counting the data information in the step 2 and the step 3 by adopting single-factor variance, analyzing and comparing the difference of each index of the significance level of the control group and the experimental group, and determining the toxicity level of 137Cs according to the difference of each index. According to the method, the toxicity of the low-radiation-activity 137Cs in the seawater is rapidly evaluated, the treatment process is simple, and the method has the characteristics of high operation repeatability and high sensitivity.

The embodiment of the invention provides an abnormal state attribution method and device, electronic equipment and a storage medium, and the method comprises the steps: obtaining abnormal feedback data, the abnormal feedback data being used for indicating a target user, and the target user being a user reporting an abnormal operation state of a client; according to the abnormal feedback data, first experimental group data are obtained, and the first experimental group data represent experimental groups of at least two function contrast experiments hitting the target user; according to the first experimental group data, a target function comparison experiment is obtained, the target function comparison experiment is determined based on the feedback permeability of the experimental group corresponding to the first experimental group data, and the feedback permeability represents the proportion of target users in the experimental group. Through the abnormal feedback data, the experiment group of the comparison function experiment hitting the target user is determined, and then the target function comparison experiment causing the abnormal operation state of the client is determined from the experiment group, so that the attribution from the abnormal operation state to the function comparison experiment is realized.

The invention discloses a CD34 + cell transport fluid and an effectiveness verification method thereof, the formula comprises human serum albumin, compound amino acid, glucose and a phosphate buffer salt solution (PBS), and the verification method comprises the following steps: step 1, obtaining CD34 + cells; 2, establishing an experimental group; 3, detecting an experimental group; step 4, obtaining a verification result; a composition of human serum albumin, compound amino acid, glucose and a phosphate buffer salt solution (PBS) is adopted as the CD34 + cell transport fluid, the effectiveness and reliability of the transport fluid are verified through tests, the transport fluid can meet the requirement that CD34 + cells can be transported for a long time under the conventional cold-chain logistics condition at the temperature of 4 DEG C, it can be guaranteed that the cell viability is larger than 90% within 24 hours, and the cell viability is larger than 90% within 24 hours. The invention provides a novel method for transporting the CD34 + cells, effectively reduces the transportation cost, and ensures the motility rate of the cells.

Sample delta monitoring is described herein. In one or more implementations, first and second experimental groups are defined in a randomized controlled trial. A first set of data indicative of a first experimental group in the randomized controlled trial is received. A second set of data indicative of a second experimental group in the randomized controlled trial is received. Based on sample counts of the first and second sets of data, an indication is generated that the experimental groups in the randomized controlled trial are skewed.

A method for analytically detecting and determining the transfection efficiency of fluorinated lipid nanoparticles (FLNPs) by utilizing multi-nuclear magnetic resonance comprises the steps of (1) performing 19F magnetic resonance spectroscopy (19F MRS) on the FLNPs to obtain a fluorine spectrum of a control group; (2) transfecting the FLNPs into cells or living mice and performing 19F MRS to obtain a fluorine spectrum of an experimental group; and (3) predicting FLNPs transfection efficiency by calculating the difference in target fluorine peak areas between the experimental and control groups. The method demonstrates excellent specificity, reproducibility, stability, and linearity, providing a robust technical foundation for large-scale screening of FLNPs-based nanomedicines.

The images represented in the image diagrams are interactive graphical user interfaces (GUIs) that visually convey information to a user related to systems for (i) creating and / or modifying and / or analyzing unit operations and data generated therefrom in manufacturing processes, such as cell and gene therapy manufacturing processes, (ii) combining live data from databases with textual information, and (iii) interactive analysis of data (e.g., patient data visualization systems) and analysis of data related to manufacturing processes. (A. Graph-Based Visualization and Interactive Data Views for Pharmaceutical Manufacturing Process Data Reconciliation) For example, in certain embodiments, the images represented in the image diagrams are associated with graph-based visualization tools that enable a user to analyze data related to one or more experiments and / or manufacturing processes used to produce pharmaceutical products and / or variations thereof. In particular, the images for graph-based visualization and data analysis GUI tools represented in the image diagrams can be used in association with GUIs that enable a user to automatically and / or semi-automatically (e.g., in conjunction with user review and / or input) generate visualizations that facilitate the examination of experiments and / or manufacturing processes and reconcile data generated across multiple processes and / or process runs. For example, among other things, the interactive graph-based visualization tools and their images may be provided (e.g., rendered) individually or together via one or more GUIs or windows, sub-windows, panels, etc. (Process Graph) For example, the image diagram illustrates a GUI that provides a visualization of a process graph. In one embodiment, the graph-based visualization tool represented in the image diagram includes generating and / or rendering a process graph that displays an experimental and / or manufacturing process for the production of pharmaceutical products, including biologics such as cell-based therapeutics and biologic drugs. The process graph includes multiple nodes, each representing a data point corresponding to a unit operation in a particular experimental and / or manufacturing process where information is collected and / or an action is performed.The image diagrams further illustrate various approaches for capturing and / or displaying these data points and how users interact with them. (Comparing and Reconciling Multiple Processes) In certain embodiments, the images depicted in the image diagrams are used as GUIs to provide graph-based visualization tools that provide comparison and / or reconciliation of data from multiple experiments and / or manufacturing processes, e.g., in an automated and / or semi-automated manner (e.g., coupled with user interactions such as review and selection actions). Among other things, the images depicted in the image diagrams include designs that overlay multiple graph processes, structurally compare them, and reconcile them based on data points. For example, the images depicted in the image diagrams may provide rendering data created by process comparison and reconciliation tools that (e.g., automatically) identify and address discrepancies, missing data, or anomalies, which can be used to generate a harmonized data set for further analysis, such as mathematical modeling. Thus, among other things, the graph-based visualization tools provided in the images depicted in the image diagrams address the challenges presented by unreconciled data across multiple experiments and / or manufacturing processes and / or within a single process that may be performed under varying conditions. Achieving automated reconciliation of such data is a significant challenge that, if not addressed, hinders effective and accurate analysis, which, in turn, can dramatically impact a user's and / or organization's ability to optimize and / or maintain manufacturing process quality and / or develop new processes. In particular, the images presented in the graph-based visualizations and the graphical representations that present them aid in adjusting sampling points to maximize overlay for effective comparisons and / or, in certain embodiments, identify overlapping points in existing data for effective real-time analysis. For example, the graphical representations show examples of multiple levels of data views and clickable / expandable pop-ups. In particular, in certain embodiments, the graphical representations are associated with GUIs that integrate the ability to collect and link actual data with process diagrams.For example, multiple levels of data can be viewed in an interactive and dynamic manner. For example, images presented in pictorial diagrams provide a high-level view, and while not all data may be directly visible, they provide clickable / expandable, customized, dynamic nodes for each node type, allowing users to simultaneously inspect and analyze collected and / or input data. In this manner, images presented in pictorial diagrams facilitate the identification and analysis of differences between processes. In some embodiments, structural differences between different processes indicate variations in conditions (e.g., temperature, duration, chemical concentrations), as well as the sequence and / or presence of certain steps. While unit operations (basic steps or stages in a process) may be generally similar to other processes, unique conditions and / or sequences can significantly affect the outcome, or the nature of the product or result. Thus, images presented in pictorial diagrams that provide visual display tools can be extremely useful in process optimization, troubleshooting, and ensuring that a process meets desired specifications. For example, changing the device that performs a unit operation and / or certain parameter values ​​within the unit operation (e.g., rotation speed, total volume, duration, etc.) can have a significant impact on the quality, recovery, efficacy, etc. of the output of that unit operation, which in turn can affect characteristics such as the biological / potency of the product, and additionally or alternatively, factors such as the cost of production, the number of doses produced per manufacturing run, and the like. Thus, among other things, images depicted in pictorial diagrams can be associated with and provided with GUIs that present generated data, such as automatically generated data (e.g., using ontologies), which helps to identify commonalities and / or differences between studies and facilitates performing analyses to determine, for example, whether device or parameter changes have significant impacts.In particular, as described herein, a graph-based visualization tool represented in a pictorial diagram provides a user with a visual representation of one or more manufacturing processes via a graph-based approach that easily communicates and highlights differences in conditions and unit operations, as well as their nature. For example, an image represented in a pictorial diagram may include visual features that highlight unreconciled data points. This approach facilitates the identification and correction of data reconciliation issues, thereby streamlining data analysis for research and process development conducted in the creation and production of pharmaceuticals, such as cell-based therapeutics and biologic drugs. (i. Process Graph with Interactive Nodes) The pictorial diagram illustrates an example of a graph-based visualization of a manufacturing process. As shown in the pictorial diagram, a manufacturing process can be represented and displayed via a process graph. Each node in the process graph displays a data point corresponding to a unit operation in the particular manufacturing process that it (e.g., the process graph) represents. The node may include information about the current data state and content (e.g., in real time) of the data point it represents. Within a graph-based visualization, nodes can be dynamic, such that, for example, a user interaction with a particular node (e.g., a mouse hover, click, touchscreen tap or long press, etc.) triggers the display of a tooltip indicating the current data state for the displayed data point, including data collected at various stages of the manufacturing process. Process graphs can be rendered and used for experiment design and process execution to outline complex manufacturing experiments over multiple days of manufacturing procedures and to visualize and track different stages of a real-time experiment.Experimental Overview: In some embodiments, a graph is displayed as an experimental overview, providing a high-level overview of an experiment, including the process steps and (e.g., approximate) order in which they were performed, the dates particular process steps were performed, how the process steps relate to one another (e.g., the top half of FIG. 1A ), and an overview of the various states / arms evaluated during the experiment and how those states relate to one another (e.g., the bottom half of FIG. 1A ). Timeline: In some embodiments, a process graph may include a timeline, displaying multiple timepoints, such as the days, during which a particular experiment or manufacturing process represented by the graph was performed. As shown in the image depicted in the pictorial diagram, the timeline may be displayed along the horizontal axis, with labeled circular icons used to visually represent individual timepoints (e.g., days of execution from day 1 through day 21). Other ways of visually displaying the timeline may be used, for example, along the vertical axis and / or using other shaped icons, other units (e.g., hours, weeks, etc.). Process Unit Operations: In some embodiments, a process graph may visually identify individual process unit operations performed during a manufacturing process. Individual process unit operations may be displayed, for example, through a combination of text labels and icons or markings that convey the particular unit operations performed and, optionally, the time at which they are carried out and / or their (e.g., temporal) relationship with respect to other unit operations. For example, the graph-based visualization shown in the image depicted in the pictorial diagram includes a series of text labels along the top row (of nodes) identifying various unit operations such as "Material Preparation," "Start-Up," "Transduction," and "Compounding." In one embodiment, as shown in the image depicted in the pictorial diagram, for example, the text labels also include a numerical component and identify the particular day on which each unit operation is performed, and the text labels are arranged sequentially from left to right along the horizontal axis to mark the order in which the operations are performed over time.The vertical dotted lines extending downward from each text label provide a visual guide for the expected schedule for each unit operation and / or a temporal mapping of the manufacturing process. (Data Points (Nodes)) As shown in the images depicted in the pictorial diagrams, data points in the manufacturing process associated with a particular unit operation and from which pertinent information (measurements and / or recorded observations) is collected are represented via nodes. Nodes may be rendered as icons such as filled circles as shown in the images depicted in the pictorial diagrams. In the images depicted in the pictorial diagrams, each circle is a node and is positioned so as to be visually aligned with a particular unit operation. That is, in the images depicted in the pictorial diagrams, it is located on a vertical dotted line extending downward from a text label identifying a particular unit operation, thereby identifying the data point related to that particular unit operation. (Connectivity) In some embodiments, the process graph may display the dependency or sequence of material and / or data flow from one unit operation to another via rendered connections between the various nodes. For example, as shown in the image depicted in the pictorial diagram, node connectivity may be rendered as lines connecting nodes across a timeline. (Data Connection Points) Specific points along the process where data is collected are marked, such as important checkpoints for quality control or measurements required for process evaluation. (Arms) In some embodiments, a process graph may include and / or display one or more (e.g., separate) arms, each representing a different experimental condition and / or baseline process variation. For example, in the image depicted in the pictorial diagram, the arms are rendered as various smaller graphs positioned below the timeline. Each line in the arms section indicates a different arm / condition as defined by the operator.Labels are provided to help clarify the focus of these steps and / or to distinguish and identify nodes as belonging to one condition, so that corresponding data collected from the laboratory are placed in the correct node and we do not mix data across conditions. In this case, the base process may be the step following a standard or control process, while other processes are steps that make experimental changes to that process or supplement the base process (e.g., making media, preparing materials, etc.). (Baseline Process and Base Process Graph) A baseline process may be a control and / or standard procedure and may be rendered as a base process graph. Text labels, color schemes, icon styles, positioning, and the like may be used to visually identify the baseline process, such as in graph-based visualizations. For example, in images presented in pictorial diagrams, the baseline process is identified and displayed as a node line directly below the timeline. In process graphs of images presented in pictorial diagrams, the baseline process may be the standard process against which other variations are compared. Variations and Outputs / Endpoints In some embodiments, a graph-based visualization can include one or more auxiliary subgraphs, each corresponding to and representing variations to experimental conditions and / or baseline versions of a manufacturing process. For example, the image depicted in the image diagram shows auxiliary subgraphs displaying variations labeled as "Ver1.1," "Ver1.2," "Ver2.1," "Ver2.3," etc., and "Condition 1," "Condition 2," "Condition 3," etc., representing different experimental arms or conditions. In this manner, the graph-based visualization tool can be used to communicate variations in materials used, process conditions, or specific unit operations performed. Additionally or alternatively, endpoints and / or outputs of different processes can also be displayed (e.g., via endpoint graphs).For example, as shown in the image depicted in the pictorial diagram, a series of nodes labeled "Out.1" and "Out.2" represent different endpoints and / or outputs of a process, such as different ways of processing or storing a final product. For example, in the exemplary subgraph shown in the image depicted in the pictorial diagram, lines refer to experimental conditions or interrelated subsets of a process, such as preparing materials (e.g., media) to feed a cell-containing process. Arm / condition sections help orient operators to the specific task being performed, and by identifying various arms in a descriptive manner, data collected in the lab are entered into corresponding nodes, and numbers / quantities, etc., are not mixed between conditions. Process graphs therefore facilitate the visualization and management of complex manufacturing processes. Among other things, they allow researchers to track the progress of experiments, compare different conditions or variations side by side, and ensure that data is systematically collected at designated points throughout the process. The ability to visualize the entire process in this way helps identify bottlenecks, ensure consistency, and facilitate data-driven decision-making.

The application discloses an analysis method, device and equipment of core molecules in the aging process, and a medium, and relates to the technical field of aging analysis. The method comprises the following steps: obtaining original data, dividing the original data into a control group and a plurality of experimental groups, and preprocessing the original data; performing aging mode clustering on the preprocessed original data to obtain a clustering result; performing duplicate removal GO enrichment analysis on each clustering mode, and visualizing the analysis result; taking the union of the molecular data of each experimental group after missing value screening and the molecular data of the control group after missing value screening, and analyzing the molecular data in the union through a differential analysis method to obtain a differential analysis result; performing correlation analysis on each clustering mode to obtain a correlation analysis result; and determining core molecules related to aging according to the correlation analysis result and the differential analysis result. The method can improve the accuracy of aging analysis.

The invention belongs to the technical field of biotechnology, and discloses a peanut peptide for promoting cell development, which is characterized in that the sequence of the peanut peptide is Met Ala Ser Val Thr Gly Pro Ser Ser Ala Leu Ala Asp Ser Ile Gly, through the accurately designed amino acid sequence, the peanut peptide constructs a molecular level adaptation mechanism with a cell surface receptor, triggers a cascade reaction of a key signal channel of phosphatidylinositol-3 kinase PI3K, and can promote cell development. The activation effect not only accelerates the process of a cell cycle and increases the proportion of DNA synthetic cells in an S phase by 40% or more, but also directionally induces the mesenchymal stem cells to differentiate into functional cells such as muscle cells and nerve cells by up-regulating transcription factors MyoD and NeuroD1, in a three-dimensional cell culture model, the cell migration rate of an experimental group added with 200 [mu] g / mL peanut peptide is increased by 58% compared with a control group, and the cell migration rate of the experimental group added with 200 [mu] g / mL peanut peptide is increased by 30% or more compared with that of the control group. The branch density of the formed vascular-like network is increased by 3 times, and meanwhile, the test further proves that the peanut peptide has the function of promoting cell development and shows remarkable optimization capability on a tissue regeneration microenvironment.

The invention discloses a down-regulated CDC20-based breast cancer cell ferroptosis sensitivity detection method, and belongs to the technical field of detection methods, and the method comprises the following steps: cell grouping and transfection: culturing a breast cancer cell system, and setting an experimental group and a transfection negative control group; wherein in the experimental group, CDC20-siRNA transfection is carried out on breast cancer cells; an experimental group with the CDC20 relative expression quantity lower than 0.5 is screened through Western blot to serve as an optimal experimental group, and subsequent experiments are conducted; and then ferroptosis induction and ferroptosis induction and inhibition are carried out, and related detection is carried out. According to the invention, CDC20 is used as a regulation target of breast cancer ferroptosis sensitivity for the first time, and the target limitation of a traditional method is broken through; and the reliability and repeatability of a detection result are ensured through a standardized operation process and closed-loop verification logic.

The present application relates to the application of long-chain non-coding RNA HILAR inhibitor in the preparation of drugs for preventing or / and treating lung adenocarcinoma metastasis. The present application provides specific intervention means for HILAR, and verifies the effectiveness of inhibiting lung adenocarcinoma metastasis: after the expression of HILAR is targeted and silenced in vitro by small interfering RNA technology, the invasion ability of lung adenocarcinoma cells is significantly inhibited, and the metastasis phenotype is obviously reversed; more importantly, through the delivery of short hairpin RNA by adeno-associated virus vector, the formation and development of lung metastasis are effectively reduced in a lung adenocarcinoma metastasis mouse model, and the in vivo imaging shows that the tumor luminescence signal intensity of the experimental group is continuously lower than that of the control group, and the overall survival condition of the animal is improved.

The invention discloses application of bitter gourd exosomes in regulating intestinal flora. The method comprises the following steps: establishing an Alzheimer's disease mouse model, injecting the extracted balsam pear exosome into the mouse body in a gavage manner to serve as an experimental group drug, taking normal saline as a model negative control group, detecting the change of the intestinal flora of the AD mouse by applying a 16S amplicon sequencing principle, and detecting the change of the intestinal flora metabolite of the AD mouse by applying an LS-MS technology. An open field experiment, a nesting experiment and a water maze experiment are adopted to verify the treatment effect of the balsam pear exosome on AD mouse intestinal flora and metabolic level changes thereof. Results prove that the bitter gourd exosome extracted by the invention can effectively improve the intestinal flora micro-ecology of AD mice; the compound can be used for preparing a microecological preparation for regulating intestinal flora of neurodegenerative diseases such as Alzheimer's disease, Parkinson's disease, Huntington's disease, amyotrophic lateral sclerosis, different types of spinal cerebellar ataxia and the like and diseases such as cerebral apoplexy, cerebral injury, epilepsy, tumor and the like.

The invention discloses a gene expression data difference analysis method and system. The method comprises the following steps: acquiring biological expression data and corresponding sample grouping information; preprocessing the gene expression data and dividing the gene expression data into an experimental group and a control group; carrying out independent intra-group abnormal value identification and elimination on the preprocessed expression data; performing independent difference analysis on the expression data before and after the abnormal values are removed to obtain two groups of verification results; and performing multiple correction on the two groups of verification results to obtain a final verification result and output statistical information. The noise problem in gene expression data can be effectively solved, and the accuracy and biological significance of difference analysis are improved. The method has remarkable advantages especially in analysis of gene expression data of small samples and non-normal distribution, and is extremely suitable for biological data capable of being longitudinally compared. The final analysis result not only has high statistical reliability, but also can provide solid data support for subsequent biological research and experimental design.

The present application relates to the field of radioactive toxicity detection, and more particularly to a method for evaluating low-activity radioactive 137 Cs toxicity based on marine Oryzias latipes, which comprises the following steps: step 1, setting the breeding conditions of Oryzias latipes, starting the exposure experiment in the adjusted exposure parameters of the radioactive 137 Cs; step 2, observing the reproductive state parameters of Oryzias latipes after the exposure experiment; step 3, dissecting the Oryzias latipes to obtain gonadal tissue; step 4, analyzing and comparing the significant level differences of each index of the control group and the experimental group by using single factor variance statistics of the data information in steps 2 and 3, and determining the toxicity level of the radioactive 137 Cs by the index differences. The present application realizes rapid evaluation of low-activity radioactive 137 Cs toxicity in seawater, and has the characteristics of simple processing process, high operation repeatability and high sensitivity.

The invention discloses an in-vitro biological efficacy evaluation method suitable for evaluating the efficacy of mesenchymal stem cells for treating systemic lupus erythematosus, and relates to the technical field of mesenchymal stem cell detection. The in-vitro biological efficacy evaluation method suitable for evaluating the efficacy of the mesenchymal stem cells for treating systemic lupus erythematosus comprises the following steps: S1, large-scale production of the mesenchymal stem cells; s2, sorting the B cells; s3, activating the cells B; s4, co-culturing the mesenchymal stem cells and the activated B cells, and taking a co-culture group as an experimental group; s5, detecting, analyzing and evaluating: detecting the regulation of the mesenchymal stem cells on the B cells, and analyzing and evaluating statistical data; b cell proliferation is stimulated through in-vitro sorting, the morbidity state of systemic lupus erythematosus (SLE) is simulated, in-vitro biological efficacy is detected through co-culture with mesenchymal stem cells, the method is rapid and simple, and the curative effect of mesenchymal stem cells of different sources can be evaluated.

The invention relates to the technical field of biological analysis, in particular to a method for analyzing methylmercury-tolerant key metabolites of tetrahymena thermophila. The method comprises the following steps: respectively culturing tetrahymena thermophila in a culture medium containing methyl mercury to respectively obtain experimental groups; culturing tetrahymena thermophila in a culture medium without methyl mercury to obtain a control group; then carrying out pretreatment on tetrahymena thermophila of the experimental group and the control group, then carrying out detection and quality control, respectively collecting data of metabolites of the experimental group and the control group, and then carrying out data processing; and finally, screening the differential metabolites of the experimental group and the control group, and then carrying out pathway enrichment analysis by adopting KEGG to obtain the change of the metabolic pathway related to the response of the tetrahymena thermophila to the methylmercury stress, and further selecting the key metabolite related to the metabolic pathway as the key metabolite related to the methylmercury thermophila to the tetrahymena thermophila.

The invention provides a method for screening toxic chemicals capable of inducing mucus to highly secrete by utilizing a three-dimensional cell model of a human cell line, and belongs to the technical field of biotoxicity evaluation. The method comprises the following steps: firstly, carrying out suspension culture on 16HBE cells to obtain a three-dimensional cell model, respectively adding a culture solution containing a series of samples to be tested with different concentrations, incubating for 48 hours, and detecting to obtain an exposure concentration for inhibiting the cell activity by 20%; and then exposing the three-dimensional cell model in a culture solution containing a test sample with the concentration for 36-50 hours, detecting the expression condition of the mucus marker protein MUC5AC through an immunofluorescence chemical method, analyzing whether an experimental group and a negative control group have statistical difference or not, and if the experimental group and the negative control group have statistical difference, determining that the chemical has mucus high secretion toxicity. The method is easy and convenient to operate, low in cost and high in three-dimensional model construction efficiency, in-situ detection of the cell activity and the protein markers can be directly carried out in the culture pore plate, multiple biological index testing is facilitated, and a more comprehensive and systematic testing system can be expanded.

The invention discloses a method for detecting blood entering components of a Xiaoming tablet. The method comprises the following steps: A, feeding an animal eye-protecting film, collecting serum as an experimental group after a preset time, and taking the serum of the animal which is not fed with the eye-protecting film as a control group; and B, detecting the experimental group and the control group by adopting liquid chromatography-mass spectrometry. According to the present invention, with the UFLC-Triple Q-TOF-MS / MS detection technology, on the basis of completing the structure identification and the component characterization of the full chemical components and the in-blood components of the Xiaotong extract and establishing the chemical omics database, the in-blood components of the Xiaotong extract are adopted as the ligands for simulating the molecular docking; screening and constructing a xerophthalmia biological target database and a disease-related target point set in the channel database. According to the method, parameters (including positions, sizes and the like of nodes) of an action network are counted by adopting a Network Analysis plug-in and a CentiScaPe 1.2 plug-in, an'active ingredient-target-pathway-disease 'interaction network and topological characteristics are established, drug effect characteristics of multi-level interaction of drugs are measured, and a core interaction target is predicted.

The present invention belongs to the field of microbial technology, and specifically relates to a strain of Lactobacillus rhamnosus MBP01 and its application for preventing and treating hemorrhoids. The present invention provides the application of Lactobacillus rhamnosus MBP01 or its microecological preparation with a deposit number of GDMCC NO:64725 in the preparation of products for preventing, treating, adjuvant therapy or post-procedural care of hemorrhoids. The Lactobacillus rhamnosus MBP01 provided by the present invention can improve the weight loss trend of hemorrhoid model mice, reduce anorectal swelling, reduce the rectal coefficient of the treatment experimental group, alleviate the damage of rectal tissue, lower the levels of TNF-α, IL-2, PGE2 and NO in the treatment experiment and the levels of NO, IL-1, IL-4 in the prevention experiment, and reduce the expression of TNF-α and IL-6. Therefore, Lactobacillus rhamnosus MBP01 has certain efficacy in the treatment and prevention of hemorrhoids in mice.

The invention discloses a machine learning-based tumor early screening expiration VOCs marker identification and verification method. The method comprises the steps of obtaining and processing high-dimensional full-spectrum expiration VOCs data; a generalized linear model is adopted to evaluate the influence of the queue correlation difference on the expiratory VOCs data, and VOCs with significant interaction are removed; screening potential expired VOCs biomarkers with significant difference between an experimental group and a control group by adopting a difference volcano plot method in which a kernel weighting function is introduced; a Boruta feature screening algorithm based on a random forest is adopted, and an expiration VOCs biomarker panel most related to the tumor is constructed; and evaluating the tumor diagnosis and grading performance of the expired VOCs biomarker panel by adopting a machine learning algorithm based on multiple underlying logics. According to the method, a marker panel construction process based on a machine learning algorithm is created, and a biomarker panel suitable for various algorithms is accurately and efficiently captured from massive expired VOCs.

The invention discloses an observation method for discussing the curative effect of a graphene acupoint patch on primary dysmenorrhea based on the acupoint theory, and mainly relates to the technical field of traditional Chinese medicine external treatment. Comprising the following steps of: screening and grouping subjects: formulating a primary dysmenorrhea diagnosis standard, screening the subjects according to the standard, dividing the subjects into an experimental group and a control group according to a random number table method, and ensuring that the two groups have no statistical difference in baseline data such as age, disease course and disease severity. The beneficial effects of the invention are that specific acupoints are selected for application according to the acupoint theory. Graphene is used as a novel nano material, has excellent thermal conductivity, electrical conductivity and biocompatibility, and can quickly transfer energy to deep acupoints, promote qi and blood circulation and relieve dysmenorrhea symptoms. Meanwhile, specific acupuncture points such as Shenque, Guanyuan, Sanyinjiao and the like are selected for application, and deep understanding and understanding of etiology and pathogenesis of primary dysmenorrhea are achieved based on the theory of traditional Chinese medicine.

The invention provides an inhalation toxicology experiment system and experiment method for animals, and aims to evaluate the influence of drugs on the animals. According to the system, an integrated head-mounted bandage is fixed to the face of an animal, so that a biological electrode is in contact with the skin of the face of the animal, and electromyographic signals are collected. And the signal is wirelessly transmitted to the monitoring terminal through the control box, so that remote monitoring is realized. In an experiment, medicine is added into the aerosol generator and converted into fine particles, the fine particles are sent into the exposure box through the air supply device, and animals are exposed in the environment for a certain time. During the period, the system continuously monitors the aerosol concentration and the environmental oxygen content to ensure stable experimental conditions. And the toxic effect of the medicine is analyzed by comparing the change of the electromyographic signals of the control group and the experimental group. An advanced signal processing technology, such as band-pass filtering, independent component analysis and the like, is adopted to extract features from the electromyographic signals, and a classifier is trained by using a machine learning method to distinguish normal electromyographic signals from electromyographic signals influenced by drugs, so that the accuracy and reliability of experimental results are improved.

A device and method are taught for stimulating sympathetic nerves toward mitigating negative impacts to hematopoiesis. An autonomic nerve actuator and stimulator system with a graphic user interface (GUI), controller circuit which converts treatment parameters into a series of Building Block Waveforms (BBW) which are output to Current / Voltage Driver Circuitry (CDC) whose electrical stimulus (ES) outputs are coupled to one or more electrodes and / or electrode arrays positioned proximal specific nerve situations. The use of this in combination with conventional chemotherapy treatments, such as use of carboplatin, was found to significantly enhance hematopoiesis, with improvements in white and red blood cell counts, platelet concentration and hemoglobin concentration, in addition to other measurable characteristics which increased survival rates in the experimental groups tested.

This invention relates to the field of biomedical technology, and in particular to the application of hD1R protein in the preparation of drugs for the treatment of AML. Addressing the current lack of systematic and in-depth research on whether hD1R protein can directly act on AML cells and whether it has a synergistic effect with existing standard chemotherapy drugs (such as anthracyclines), this invention, through a series of in vivo and in vitro experiments and the construction of a NOD / SCID mouse transplantation model, confirms that hD1R protein alone can effectively inhibit AML cell proliferation, induce apoptosis, inhibit AML cell colony formation, and downregulate the expression of the key anti-apoptotic gene Bcl2 in AML cells. It also confirms that hD1R treatment can significantly prolong the survival of model mice. Furthermore, by setting up a Dox+hD1R group (combined experimental group), it is confirmed that when hD1R protein is used in combination with anthracycline chemotherapy drugs, it exhibits significant synergistic effects in inhibiting AML cell proliferation, promoting AML cell apoptosis, downregulating the expression of the anti-apoptotic gene Bcl2 in AML cells, and inhibiting AML cell colony formation.